Shares of the largest generic drug company in the world, Teva Pharmaceuticals (NYSE: TEVA ) , are down more than 7.5% in the last 12 months. This drop largely has to do with fears that biosimilars of the multiple sclerosis drug Copaxone, which currently accounts for a fifth of Teva's top line, may enter the market in the next couple of years. But what growth opportunities does the company have in the future, and what moves can it make to boost investor confidence? Analysts David Williamson and Max Macaluso discuss this topic in this segment from the Motley Fool's health-care show Market Checkup.
Looking for more dividend ideas?
One of the best parts of owning some big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report, "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.